Table 2.

Univariate logistic proportional hazards regression analysis in the training cohort.

Characteristic		Glioma		OR (95% CI)	P-value
		Low grades	High grades
Gender	Male	89	71	Ref
	Female	78	54	0.868 (0.544–1.384)	0.551
Age (years)	<60	148	87	Ref
	≥60	19	38	3.402 (1.847–6.268)	<0.001
Tumor diameter	≤2 cm	29	17	Ref
	>2 cm	138	108	1.335 (0.697–2.556)	0.383
IDH1 mutation	Negative	58	38	Ref
	Positive	68	50	1.122 (0.649–1.942)	0.68
1p/19q codeletion	Negative	37	21	Ref
	Positive	30	26	1.527 (0.721–3.233)	0.269
Ki-67	≤10%	146	56	Ref
	>10%	21	69	8.566 (4.808–15.262)	<0.001
ATR-X	Negative	9	6	Ref	0.841
	Positive	36	27	1.125 (0.357–3.543)
CD56	Negative	4	1	Ref
	Positive	104	86	3.308 (0.363–30.147)	0.289
P53	Negative	44	24	Ref
	Positive	47	46	1.794 (0.944–3.411)	0.074
EMA	Negative	100	75	Ref
	Positive	21	17	1.079 (0.533–2.187)	0.832
GFAP	Negative	5	6	Ref
	Positive	116	79	0.568 (0.167–1.924)	0.363
WBC (109/L)a	≤7.07	102	76	Ref
	>7.07	65	49	1.012 (0.629–1.627)	0.962
RBC (1012/L)a	≤4.54	80	73	Ref
	>4.54	87	52	0.655 (0.41–1.046)	0.072
HB (g/L)a	≤134	76	66	Ref
	>134	91	59	0.747 (0.469–1.188)	0.218
PLT (109/L)a	≤223	81	74	Ref
	>223	86	51	0.649 (0.406–1.037)	0.071
Lymphocyte (109/L)a	≤1.7	68	81	Ref
	>1.7	99	44	0.373 (0.231–0.603)	<0.001
Neutrophils (109/L)a	≤4.78	115	78
	>4.78	52	47	1.333 (0.818–2.171)	0.249
NLRa	≤3.6	142	88	Ref
	>3.6	25	37	2.388 (1.347–4.235)	0.003
PLRa	≤152.7	115	75	Ref
	>152.7	52	50	1.474 (0.908–2.395)	0.117
ALU (g/L)	≤42.7	69	81	Ref
	>42.7	98	44	0.382 (0.237–0.618)	<0.001
LDH (U/L) b	≤250	126	94	Ref
	>250	41	31	1.013 (0.592–1.735)	0.961

IDH1, isocitrate dehydrogenase-1; 1p/19q co-deletion, chromosome 1 and the long arm of chromosome 19; ATRX, alpha-thalassemia/mental retardation syndrome X-linked; Ki67, nuclear proliferation antigen 67; GFAP, glial fibrillary acidic protein; EMA, epithelial membrane antigen; PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; ALU, albumin; LDH, lactate dehydrogenase.